Steroid treatment is widely used in acute cerebral infarction yet its value is controversial. High dose dexamethasone (480 mg over 12 days) was given in a double blind, randomised controlled trial to 113 consecutive eligible patients with acute cerebral infarction admitted to an acute stroke unit. Those High dose steroid treatment was ineffective in ischaemic stroke, and the data suggest that further evaluation by a larger multicentre trial is not justified.
Introduction
Few controversies in the management of acute stroke are more contentious than that concerning the use of steroids. The enthusiasm generated by early anecdotal reports'2 waned when data from controlled trials yielded conflicting results.`Steroid treatment in the form of dexamethasone is still widely administered in acute stroke. In a recent survey of 70 physicians in Toronto (35 internists and 35 neurologists) 39 (56%) prescribed steroids for stroke "sometimes," 30 (43%) "never," and one "always." Steroid treatment was usually reserved for patients with impaired consciousness due to presumed cerebral oedema.
Megadose treatment (up to 10 times the usual dose) overcomes criticism that the steroid dosage used previously was too small and too brief.6 Initial favourable reports of high dosage dexamethasone in head injury prompted the following study in patients with acute cerebral infarction. 7' Patients and methods Consecutive patients admitted to the Toronto acute stroke unit were entered into the study once informed consent from the patient or nearest relative had been obtained. Excluded were patients with (a) stroke that had occurred more than 48 Sample size-A previous study using a similar scoring system provided data for calculation of sample size.' The mean percentage change in weighted stroke scores from day 1 to day 21 was estimated for the placebo group (the usual course of the condition) and used to decide whether a 25% or a 50% therapeutic effect was more appropriate: (score day 1 -score day 21)/score day 1 (x 100) =% change in score. The mean percentage decrease in stroke score over 21 days in the placebo group was 28-6 (SEM 24 Statistical analysis-The effect of independent factors in the two groups, including active drug treatment, was evaluated by logistic regression." A log rank test and Cox regression compared the relative hazard rate of the two groups, accounting for the censoring of observations due to death or withdrawal." " Kaplan-Meier survival curves were generated to compare the two groups, both with survivors only and with survivors plus withdrawals and deaths.'4 Scores in the two survivor groups were compared using analysis of variance with data from patients with a complete set of assessments. Student's t tests evaluated the differences in the mean baseline scores, the mean final scores, and change in the mean scores in each group. Spearman correlations were performed between study groups treated as a binary variable, using the neurological scores at each observation.'
Results
Of 270 consecutive patients admitted to the stroke unit, 117 met the entry criteria and were allocated at random to receive steroid or placebo (table II) . The groups were identical except that the placebo group had significantly more cardiac disease (table III) . Seven of the 54 patients in the steroid group and six of the 59 given placebo were withdrawn because of presumed side effects (table IV) .
There was no significant difference in the death rate or in neurological outcome between the two groups, whether the survivors were evaluated separately (fig) or the scores of patients who died were included (table V) . More patients died of coning in the placebo group than in the steroid group, but this difference also was not significant (table VI).
Discussion
Previous attempts at controlled or double blind trials of steroids in stroke' 3-5 I were performed in an era when sample sizes were inadequate or when cerebral infarction could not easily be differentiated from haemorrhage. An expert group outlined the basic principles of future stroke drug trials in 1977,"1 yet their advice remained largely unheeded.
Stroke is an imprecise term encompassing various pathological states, mostly cerebral infarction and haemorrhage. Clinical diagnosis of stroke is inaccurate,' and studies are invalid without computed tomography (or at least radionuclide imaging) to confirm the lesion. The pathology of cerebral infarction and haemorrhage differs, and there is no rationale for a similar response to steroid treatment of the mass effect of haematoma and the vasogenic oedema of ischaemia.2"
The validity of drug trials in stroke depends on the qualitative and quantitative validity of the neurological assessment. The Toronto stroke scoring system correlates significantly with clinical function.9 Scoring methods are as numerous as their authors'-': some emphasise unusual sequelae of stroke such as "confusion" or urinary incontinence, or evaluate functionless variables such as pupil size or In the large study required to detect a significant effect ofsteroids on coning many patients would -be exposed to the hazards of steroids, including infection, hypoglycaemia, and gastrointestinal haemorrhage. The dubious advantage of preventing death in seriously afflicted patients would be offset by exposing a wide range of patients believed to have "stroke" to the side effects of the drug. Such indiscriminate use of steroids might also result in serious side effects in survivors who would otherwise recover uneventfully. Dyken and White abandoned an early trial of steroids in stroke because patients given the active drug fared worse than those given placebo." In a later negative study steroid induced diabetes caused serious reactive hypoglycaemia and systemic infections left permanent sequelae in some patients.5 Larger multicentre studies to identify a subgroup ofpatients who might benefit from steroids are therefore unjustified.
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SHORT REPORTS
Evidence of inherited urea cycle defect in a case of fatal valproate toxicity Liver failure deaths have occurred, mainly in children, during treatmeat with valproate.' The small number of cases with serious complications indicates that an inherited metabolic defect might be implicated.1 At therapeutic levels of valproate net production of ammonia in the kidney is increased2 and urea synthesis inhibited in healthy subjects (Hjelm et al, in preparation). Thus children with hereditary urea cycle defects might be further compromised by valproate with accelerated damage of brain tissue. Alanine was admninistered intrayenously (0-25 g/kg body weight) over 10' 20 minutes. Blood was drawnat intervals before and after the load for estimating ammonia (ion selective electrode) and urea. Urine was collected every 40 minutes for estimating orotate.' The maxmum increase in the rate of urea synthesis from preload values (f) and the time at which it occurred (i) were calculated from the increase in plasma urea concentration.' This approach allows the production of orotate to be related to the turnover of metabolitts in the urea cycle.
All three subjects responded to the alanine load with the same fand t as healthy subjects. The mother's response was maintained at increased plasma concentradions of ammonia and urinary excretion oforotate. This suggested accumulation of carbamoylphosphate in the liver, a diagnostic feature of ornithine carbamoyltransferase deficiency and provided indirect evidence that the mother was heterozygous for this deficiency (Hjelmeal, in preparation).5
Comment
Ornithine carbamoyltransferase deficiency is an X linked disorder, the most common of the urea cycle defects,'with variable expression, in female camrrers due to raidom inactivision of the X'chromosomee (Lyon, hypothesis). Thus women vary from-clinically normal to severely affected, In men the condition is often fatal in early childhood. The dead children were probably affected by this disease and valproate
